114 related articles for article (PubMed ID: 38190833)
1. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
Lancet Infect Dis; 2024 Feb; 24(2):e80-e81. PubMed ID: 38190833
[No Abstract] [Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
Stankov MV; Hoffmann M; Gutierrez Jauregui R; Cossmann A; Morillas Ramos G; Graalmann T; Winter EJ; Friedrichsen M; Ravens I; Ilievska T; Ristenpart J; Schimrock A; Willenzon S; Ahrenstorf G; Witte T; Förster R; Kempf A; Pöhlmann S; Hammerschmidt SI; Dopfer-Jablonka A; Behrens GMN
Lancet Infect Dis; 2024 Jan; 24(1):e1-e3. PubMed ID: 37995739
[No Abstract] [Full Text] [Related]
4. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
5. Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.
Atıcı S; Soysal A; Gönüllü E; Aydemir G; Öner N; Alan S; Engin H; Yıldız M; Karaböcüoğlu M
Rev Soc Bras Med Trop; 2023; 56():e00462023. PubMed ID: 37493731
[TBL] [Abstract][Full Text] [Related]
6. Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
J Infect; 2022 Jul; 85(1):e24-e25. PubMed ID: 35398406
[No Abstract] [Full Text] [Related]
7. Waning of humoral immunity depending on the types of COVID-19 vaccine.
Lim SY; Kim JY; Jung J; Yun SC; Kim SH
Infect Dis (Lond); 2023 Mar; 55(3):216-220. PubMed ID: 36625442
[TBL] [Abstract][Full Text] [Related]
8. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():839922. PubMed ID: 35309303
[TBL] [Abstract][Full Text] [Related]
9. Decline of immune humoral response after BNT162b2 vaccine.
Ferri S; Polidoro A; Ciacciarelli M; Ceratti U; Congedo V; Mele M; Coluzzi G; Spagnoli A; Iuliano L
J Infect; 2022 Apr; 84(4):e34-e35. PubMed ID: 35183610
[No Abstract] [Full Text] [Related]
10. Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents.
Van Praet JT; Vandecasteele S; De Roo A; Vynck M; De Vriese AS; Reynders M
J Infect Dis; 2021 Nov; 224(10):1690-1693. PubMed ID: 34514509
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
Miyakawa K; Kato H; Ohtake N; Jeremiah SS; Ryo A
J Infect Dis; 2023 Jan; 227(2):221-225. PubMed ID: 35978486
[TBL] [Abstract][Full Text] [Related]
13. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study.
Zelini P; Isoletta E; Volontè M; Lilleri D; Cassaniti I; Musella V; Klersy C; Baldanti F; Brazzelli V
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e294-e296. PubMed ID: 36433886
[No Abstract] [Full Text] [Related]
15. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
Woldemeskel BA; Karaba AH; Garliss CC; Beck EJ; Wang KH; Laeyendecker O; Cox AL; Blankson JN
Clin Infect Dis; 2022 Apr; 74(7):1268-1270. PubMed ID: 34293114
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
17. Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Closset M; Cabo J; Wauthier L; David C; Elsen M; Dogné JM; Douxfils J
J Med Virol; 2024 Jan; 96(1):e29365. PubMed ID: 38185981
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
Uwamino Y; Yokoyama T; Sato Y; Shibata A; Kurafuji T; Tanabe A; Noguchi M; Arai T; Ohno A; Yokota H; Namkoong H; Nishimura T; Kosaki K; Hasegawa N; Wakui M; Murata M; Matsushita H
Vaccine; 2023 Feb; 41(9):1545-1549. PubMed ID: 36732167
[TBL] [Abstract][Full Text] [Related]
19. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Silzle T; Kahlert CR; Albrich WC; Nigg S; Demmer Steingruber R; Driessen C; Fischer S
Swiss Med Wkly; 2023 Jun; 153():40090. PubMed ID: 37410944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
